Innovation is Urgently Needed in Neurology and Rare Disease
We’ve built a capital efficient precision discovery platform based in the real world
We’ve developed molecularly barcoded substrates that record the functional activity of targets
We discover functional small molecules 10X faster and 50X cheaper with 15X fewer scientists and a 40X smaller lab footprint
Small molecule screening and discovery is either stuck in the past (at large pharma screening facilities) or based on incomplete AI modeling capabilities that have been very oversold.
We've built a real-world small molecule discovery engine for a series of targets with causal human biology. Our cornerstones are capital efficient assays that measure the functional activity of targets using molecularly barcoded substrates; allowing precise, highly scalable small molecule discovery.
We’ve developed the capability to measure the effect of small molecules on the physiological function of targets for thousands of compounds in one tube
Directly measure physiological function of targets
Bi-directional precision, High accuracy, Low variability
Low cost: Inexpensive libraries, no live cells needed, small footprint, 1-2 scientists
Timing: Weeks
Series of targets in development
Additional Information
Actively screening small molecules on target #1 in rare neurodegenerative condition (target and disease ID in stealth)
Platform established for first target in first rare disease
Precise functional readouts
High accuracy
Very scalable
Low variation
Intra assay coefficient of variation < .03
Inter assay coefficient of variation < .04
Tunable response window
Actively screening diversity compound decks
Target-specific assays and substrate-specific molecular barcoding
Comprehensively built and performed in-house at Seq Therapeutics
Molecular barcoding of substrates
Small molecule screening assays
Sequencing & Analytics
Calibration Datasets (active small molecule screening data not shown)
Raw Small Molecule Screening and Calibration
Highly reactive compounds - 320 compound PAINS deck
First pass potentiator hit rate = .28%First pass inhibitor hit rate = .52% 
Control Plate Example
Coefficient of variation less than .03